Cargando…

An Economic Analysis: Is Fidaxomicin Worth the Cost?

Detalles Bibliográficos
Autores principales:	Shah, Hemal, Doyle, Joseph J., Belletti, Daniel A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905758/ https://www.ncbi.nlm.nih.gov/pubmed/24300041 http://dx.doi.org/10.1093/cid/cit773

Ejemplares similares

Reply to Worth et al
por: Mitchell, Brett G., et al.
Publicado: (2014)

Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection
por: Nathwani, Dilip, et al.
Publicado: (2014)

467 Analysis of Clinical and Economical Outcomes of Fidaxomicin Use for Clostridium difficile infections
por: Flaherty, Sarah, et al.
Publicado: (2014)

Antimicrobial Activities of Fidaxomicin
por: Goldstein, Ellie J. C., et al.
Publicado: (2012)

Hounsfield units in pseudo subarachnoid hemorrhage: worth looking for
por: Senthilkumaran, Subramanian, et al.
Publicado: (2017)

Fidaxomicin to prevent recurrent Clostridioides difficile: what will it cost in the USA and Canada?
por: Patel, Devangi, et al.
Publicado: (2023)

675. The Fidaxomicin Cascade: Analysis of Success Rates and Barriers of Fidaxomicin Discharge Prescriptions for Inpatients Diagnosed with Clostridiodes Difficile
por: Cook, Ellen, et al.
Publicado: (2023)

Letter from Dr. E. J. B. Ft. Worth
Publicado: (1886)

Interrupting methotrexate to improve immunity after COVID-19 booster vaccination: is it really worth it?
por: Jorda, Anselm, et al.
Publicado: (2022)

Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infection (C. difficile-associated diarrhoea) in Ireland
por: van Engen, Anke, et al.
Publicado: (2015)

The cost-effectiveness challenge: is it worth it?
por: Knapp, Martin
Publicado: (2015)

Measles Immunization: Worth Considering Containment Strategy for SARS-CoV-2 Global Outbreak
por: Hanker, Varnit S.
Publicado: (2020)

Familial Steatocystoma Multiplex Generalisita Suppuritiva: Oral Rifampicin and Clindamycin Combination Worth a Trial
por: Ahmed, Ghazal, et al.
Publicado: (2021)

In vitro activity of fidaxomicin and combinations of fidaxomicin with other antibiotics against Clostridium perfringens strains isolated from dogs and cats
por: Álvarez-Pérez, Sergio, et al.
Publicado: (2023)

Novel fidaxomicin antibiotics through site-selective catalysis
por: Dailler, David, et al.
Publicado: (2021)

Clinical and Economic Outcomes After Implementation of a Fidaxomicin Treatment Optimization and Access Pathway at a US Hospital System
por: McDaniel, Lauren F., et al.
Publicado: (2022)

Fidaxomicin Is an Inhibitor of the Initiation of Bacterial RNA Synthesis
por: Artsimovitch, Irina, et al.
Publicado: (2012)

Fidaxomicin Inhibits Spore Production in Clostridium difficile
por: Babakhani, Farah, et al.
Publicado: (2012)

Fidaxomicin - the new drug for Clostridium difficile infection
por: Vaishnavi, Chetana
Publicado: (2015)

Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
por: Oliver, Meredith B, et al.
Publicado: (2022)

Cost-Benefit Analysis of the LHC to 2025 and beyond: Was it Worth it ?
por: Prof. Florio, Massimo
Publicado: (2015)

Are fishery management upgrades worth the cost?
por: Mangin, Tracey, et al.
Publicado: (2018)

Correction to: Clinical and Economic Outcomes After Implementation of a Fidaxomicin Treatment Optimization and Access Pathway at a US Hospital System
por: McDaniel, Lauren F., et al.
Publicado: (2022)

Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Colitis
por: Khoo, Teresa, et al.
Publicado: (2017)

Extracorporeal Membrane Oxygenation for Critically Ill Patients with COVID-19–related Acute Respiratory Distress Syndrome: Worth the Effort?
por: Falcoz, Pierre-Emmanuel, et al.
Publicado: (2020)

Extracorporeal Membrane Oxygenation for Critically Ill Patients with COVID-19–related Acute Respiratory Distress Syndrome: Worth the Effort!
por: Wengenmayer, Tobias, et al.
Publicado: (2020)

693. Clinical and Economic Outcomes Associated with Fidaxomicin in Comparison to Vancomycin, Metronidazole, and FMT: a Systematic Literature Review
por: Li, Qinghua, et al.
Publicado: (2023)

A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany
por: Watt, Maureen, et al.
Publicado: (2016)

Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection
por: Zhanel, George G, et al.
Publicado: (2015)

Safety Analysis of Fidaxomicin in Comparison With Oral Vancomycin for Clostridium difficile Infections
por: Weiss, Karl, et al.
Publicado: (2012)

Semisynthetic Analogs of the Antibiotic Fidaxomicin—Design, Synthesis, and Biological Evaluation
por: Dorst, Andrea, et al.
Publicado: (2020)

Emerging therapies for Clostridium difficile infection – focus on fidaxomicin
por: Chaparro-Rojas, Fredy, et al.
Publicado: (2013)

Is Scale-Up Worth It? Challenges in Economic Analysis of Diagnostic Tests for Tuberculosis
por: Dowdy, David W., et al.
Publicado: (2011)

Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness
por: Cornely, Oliver A, et al.
Publicado: (2018)

A multi-center study of fidaxomicin use for Clostridium difficile infection
por: Shah, Dhara N., et al.
Publicado: (2016)

Fidaxomicin Use and Clinical Outcomes for Clostridium difficile–Associated Diarrhea
por: Eiland, Edward H., et al.
Publicado: (2015)

Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain
por: Rubio-Terrés, Carlos, et al.
Publicado: (2019)

Pneumothorax and barotrauma in invasively ventilated patients with COVID-19
por: Belletti, Alessandro, et al.
Publicado: (2021)

Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
por: Cornely, Oliver A., et al.
Publicado: (2012)

679. Retrospective Analysis of Vancomycin and Fidaxomicin for the Treatment of Recurrent Clostridioides difficile Infection
por: Fabian, Amy, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0809i0pddl6014dofqocsogk5e